Literature DB >> 17102945

The contribution of genotypes at the MICA gene triplet repeat polymorphisms and MEFV mutations to amyloidosis and course of the disease in the patients with familial Mediterranean fever.

Nuran Turkcapar1, Timur Tuncali, Sim Kutlay, Basak Yalcin Burhan, Gulay Kinikli, Sehsuvar Erturk, Murat Duman.   

Abstract

OBJECTIVE: To evaluate the effects of MEFV genotypes and the major histocompatibility complex class I chain-related gene A (MICA) triplet repeat polymorphism on the severity and clinical features of familial Mediterranean fever (FMF) and amyloidosis in a group of Turkish FMF patients.
METHODS: We evaluated 105 adult FMF patients (with or without amyloidosis, 33 and 72, respectively) along with 107 healthy controls who were neither related to the patients nor had a family history of FMF or Behcet's disease. After recording the demographic and clinical data, the predominant mutations in the MEFV gene locus (M694V, M680I, V726A, M694I, and E148Q) were investigated by direct sequencing. MICA transmembrane polymorphisms in exon 5 were studied by vertical gel electrophoresis and fragment analysis of the amplicons obtained from MICA locus with appropriate primers.
RESULTS: Earlier age at onset, increased frequency of attacks, arthritis attacks, erysipelas-like erythema, increased severity scores and amyloidosis were significantly more common in M694V homozygous patients compared to the patients not M694V homozygous (P = 0.005, OR 4.55; P = 0.001, OR 7.60; P = 0.003, OR 4.57; P = 0.002, OR 7.58; P = 0.004, OR 5.15 and P = 0.018, OR 3.33, respectively). We did not detect any modifying effects of MICA alleles as an independently risk factor on the amyloidosis development. However, when we examined the effects of MICA alleles on the course of the disease and development of amyloidosis in the M694V homozygous patients, A5 allele had a protective effect against the development of amyloidosis (P = 0.038, OR(adj) 0.26 with A5 and P = 0.009, OR(adj) 4.42 without A5).
CONCLUSION: Though the effects of the MEFV genotypes seem clear, there are definitely other modifying factors or genes on the development of amyloidosis and on the course of the disease. For example, some MICA alleles have a protective effect on the prognostic factors in FMF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102945     DOI: 10.1007/s00296-006-0255-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  An activating immunoreceptor complex formed by NKG2D and DAP10.

Authors:  J Wu; Y Song; A B Bakker; S Bauer; T Spies; L L Lanier; J H Phillips
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

2.  The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever.

Authors:  Ruth Gershoni-Baruch; Riva Brik; Nurit Zacks; Maruan Shinawi; Merav Lidar; Avi Livneh
Journal:  Arthritis Rheum       Date:  2003-04

3.  Association of the MIC-A gene and HLA-B51 with Behçet's disease in Arabs and non-Ashkenazi Jews in Israel.

Authors:  R Cohen; S Metzger; M Nahir; T Chajek-Shaul
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

4.  Polymorphism of transmembrane region of MICA gene and Kawasaki disease.

Authors:  Y Huang; Y J Lee; M R Chen; C H Hsu; S P Lin; T C Sung; S C Chang; J G Chang
Journal:  Exp Clin Immunogenet       Date:  2000

5.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

6.  Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease.

Authors:  G Gambelunghe; A Falorni; M Ghaderi; S Laureti; C Tortoioli; F Santeusanio; P Brunetti; C B Sanjeevi
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

7.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

8.  MICA4/HLA-DRB1*04/TNF1 haplotype is associated with mixed connective tissue disease in Swedish patients.

Authors:  Adla B Hassan; Liene Nikitina-Zake; Leonid Padyukov; Göran Karlsson; Manu Gupta; Ingrid E Lundberg; Carani B Sanjeevi
Journal:  Hum Immunol       Date:  2003-02       Impact factor: 2.850

9.  Infevers: an evolving mutation database for auto-inflammatory syndromes.

Authors:  Isabelle Touitou; Suzanne Lesage; Michael McDermott; Laurence Cuisset; Hal Hoffman; Catherine Dode; Nitza Shoham; Ebun Aganna; Jean-Pierre Hugot; Carol Wise; Hans Waterham; Denis Pugnere; Jacques Demaille; Cyril Sarrauste de Menthiere
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

10.  Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients.

Authors:  Engin Yilmaz; Banu Balci; Sim Kutlay; Seza Ozen; Sensuvar Ertürk; Ayse Oner; Nesrin Beşbaş; Ayşin Bakkaloğlu
Journal:  Turk J Pediatr       Date:  2003 Jul-Sep       Impact factor: 0.552

View more
  3 in total

1.  Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever.

Authors:  Hale Sakallı; Oznur Kal
Journal:  Clin Rheumatol       Date:  2013-04-17       Impact factor: 2.980

Review 2.  Update on Pyrin Functions and Mechanisms of Familial Mediterranean Fever.

Authors:  Gayane Manukyan; Rustam Aminov
Journal:  Front Microbiol       Date:  2016-03-31       Impact factor: 5.640

3.  Genome sequencing unveils mutational landscape of the familial Mediterranean fever: Potential implications of IL33/ST2 signalling.

Authors:  Meenakshi Umar; Andre Megarbane; Jingxuan Shan; Najeeb Syed; Eliane Chouery; Elbay Aliyev; Puthen Jithesh; Ramzi Temanni; Issam Mansour; Lotfi Chouchane; Aouatef Ismail Chouchane
Journal:  J Cell Mol Med       Date:  2020-08-27       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.